What does SENT mean in EUROPEAN
SENT (Sentinel European Node Trial) is a clinical research study that evaluates the use of a new injectable treatment for patients with advanced non-small cell lung cancer (NSCLC). The trial is conducted at multiple centers across Europe and is sponsored by the pharmaceutical company Roche.
SENT meaning in European in Regional
SENT mostly used in an acronym European in Category Regional that means Sentinel European Node Trial
Shorthand: SENT,
Full Form: Sentinel European Node Trial
For more information of "Sentinel European Node Trial", see the section below.
SENT: Meaning, Full Form, and Definition
- SENT stands for Sentinel European Node Trial.
- It is an acronym for the clinical trial that investigates the effectiveness and safety of durvalumab in treating patients with unresectable stage III NSCLC.
- Durvalumab is a monoclonal antibody that targets the PD-L1 protein, which is often expressed on tumor cells and immune cells in NSCLC.
Objectives of the SENT Trial
The primary objective of the SENT trial is to assess the efficacy and safety of durvalumab in improving progression-free survival (PFS) in patients with unresectable stage III NSCLC who have not received prior systemic therapy. Secondary objectives include evaluating the overall survival, objective response rate, and safety profile of durvalumab in this patient population.
Eligibility Criteria for the SENT Trial
Eligible patients for the SENT trial must meet the following criteria:
- Histologically confirmed unresectable stage III NSCLC
- No prior systemic therapy for NSCLC
- Adequate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Essential Questions and Answers on Sentinel European Node Trial in "REGIONAL»EUROPEAN"
What is the Sentinel European Node Trial (SENT)?
SENT is a clinical trial designed to evaluate the safety and efficacy of a new investigational therapy for the treatment of acute ischemic stroke. The trial will assess the ability of the therapy to reduce brain damage and improve functional outcomes in patients with stroke.
Who is eligible to participate in the SENT trial?
To be eligible for the SENT trial, participants must meet specific criteria, such as having suffered an ischemic stroke within a certain timeframe, and meeting specific medical criteria. Detailed eligibility requirements are determined by the study protocol and are subject to evaluation by the investigator.
What are the potential benefits of participating in the SENT trial?
Participating in the SENT trial offers potential benefits, including access to an investigational therapy that may not be widely available outside of the study. Additionally, participants will be closely monitored by healthcare professionals, and their data will contribute to the advancement of medical research in stroke treatment.
Are there any risks associated with participating in the SENT trial?
As with any clinical trial, there are potential risks associated with participating in the SENT trial. These risks will be carefully explained to potential participants before they make a decision about enrolling in the study.
Where can I find more information about the SENT trial?
For more information about the SENT trial, including eligibility criteria, trial locations, and contact information, please visit the trial's website or consult with a healthcare professional.
Final Words: The SENT trial is a significant clinical study that aims to determine the efficacy and safety of durvalumab in patients with advanced NSCLC. The results of this trial will provide important information on the potential of durvalumab as a treatment option for this patient population.